The United States of America, As Represented by the Secretary, Department of Health and Human Services

The United States of America As Represented by the Department of Health

National Institutes of Health, Office of Technology Transfer

Thomas G Ksiazek

Stuart T Nichol

Pierre E Rollin

James A Comer

Cesar G Albarino

Brian H Bird

Christina F Spiropoulou

Larry J Anderson

Anthony Sanchez

Cara Carthel Burns

William Allan Nix

Raymond Campagnoli

M Steven Oberste

Paul A Rota

Suxiang Tong

Mark A Pallansch

Dean D Erdman

William J Bellini

Cynthia Goldsmith

Stephan S Monroe

Jonathan S Towner

Qi Chen

Shannon L Emery

Charles D Humphrey

Joseph P Icenogle

Sergey Morzunov

Teresa C T Peret

Sherif R Zaki

Luanne Elliott

Michael D Bowen

Eugeny Ravkov

Byron T Cook

Jeanette Guarner

Richard F Meyer

Christopher D Paddock

Wun-Ju Shieh

Compositions and methods including and related to the Ebola Bundibugyo virus (EboBun) are provided. Compositions are provided that are operable as immunogens to elicit and immune response or protection from EboBun challenge in a subject such as a primate. Inventive methods are directed to detection and treatment of EboBun infection.

Human ebola virus species and compositions and methods thereof

Described herein are recombinant RVF viruses comprising deletions in one or more viral virulence genes, such as NSs and NSm. The recombinant RVF viruses, generated using a plasmid-based reverse genetics system, can be used as vaccines to prevent infection of RVF virus in livestock and humans. As described herein, the recombinant RVF viruses grow to high titers, provide protective immunity following a single injection and allow for the differentiation between vaccinated animals and animals infected with wild-type RVF virus.

Recombinant rift valley fever (RVF) viruses and methods of use

Human Ebola virus species and compositions and methods thereof

Recombinant rift valley fever (RVF) viruses and methods

Recombinant Rift Valley fever (RVF) viruses and methods of use

Disclosed herein is a newly isolated human coronavirus (SARS-CoV), the causative agent of severe acute respiratory syndrome (SARS). Also provided are the nucleic acid sequence of the SARS-CoV genome and the amino acid sequences of the SARS-CoV open reading frames, as well as methods of using these molecules to detect a SARS-CoV and detect infections therewith. Immune stimulatory compositions are also provided, along with methods of their use.

Coronavirus isolated from humans

The present invention relates to the discovery of a novel Hantavirus. In particular, the present invention relates to nucleic acids of the newly discovered virus and to nucleic acid reagents and antibodies for use in methods of detection and prevention of infection by the virus.

Polypeptides of a novel hantavirus

Strain of hantavirus nucleotide sequences thereof related probes,

The present invention relates to the discovery and isolation of a novel hantavirus designated the Bayou hantavirus. In particular, the present invention relates to nucleic acids of the newly discovered virus and to nucleic acid reagents (primers and probes), purified polypeptides and antibodies for use in methods of detection and prevention of infection by the virus. A vaccine or purified immunogenic polypeptide of the Bayou hantavirus in a pharmaceutically acceptable carrier is provided. A vector comprising the nucleic acids of the invention is provided. A method of detecting the presence of a hantavirus in a subject comprising contacting an antibody-containing sample from the subject with a purified polypeptide of the invention and detecting the reaction of the polypeptide and the antibody is provided. A method of detecting the presence of the Bayou hantavirus is provided comprising reverse transcribing viral RNA to synthesize a complementary DNA sequence followed by amplifying the DNA using primers which are selective for the Bayou hantavirus and detecting the presence of amplification, thereby indicating presence of the Bayou hantavirus in the sample.

Bayou hantavirus and related methods

The present invention relates to the discovery and isolation of a novel hantavirus designated the Black Creek Canal hantavirus. In particular, the present invention relates to nucleic acids of the newly discovered virus and to nucleic acid reagents (primers and probes), purified polypeptides and antibodies for use in methods of detection and prevention of infection by the virus. A vaccine or purified immunogenic polypeptide of the Black Creek Canal hantavirus in a pharmaceutically acceptable carrier is provided. A vector comprising the nucleic acids of the invention is provided. A method of detecting the presence of a hantavirus in a subject comprising contacting an antibody-containing sample from the subject with a purified polypeptide of the invention and detecting the reaction of the polypeptide and the antibody is provided. A method of detecting the presence of the Black Creek Canal hantavirus is provided comprising reverse transcribing viral RNA to synthesize a complementary DNA sequence followed by amplifying the DNA using primers which are selective for the Black Creek Canal hantavirus and detecting the presence of amplification, thereby indicating presence of the Black Creek Canal hantavirus in the sample.

Black creek canal hantavirus and related methods

Growing community of inventors

Galveston, TX, United States of America

Thomas G Ksiazek